Novel targeted therapies for the treatment of penile cancer

Bibliography

• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Pizzocaro G, Algaba F, Horenblas S, et al. EAU penile cancer guidelines 2009. Eur Urol 2010;57(6):1002-12
   PubMed Web of Science ®Google Scholar
• Kacker S, Frick KD, Gaydos CA, et al. Costs and effectiveness of neonatal male circumcision. Arch Pediatr Adolesc Med 2012;166(10):910-18
   PubMed Web of Science ®Google Scholar
• Burt LM, Shrieve DC, Tward JD. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. Int J Radiat Oncol Biol Phys 2014;88(1):94-100
   PubMed Web of Science ®Google Scholar
• Moses KA, Winer A, Sfakianos JP, et al. Contemporary management of penile cancer: greater than 15 year MSKCC experience. Can J Urol 2014;21(2):7201-6
   PubMed Web of Science ®Google Scholar
• Spiess PE; National Comprehensive Cancer Network. New treatment guidelines for penile cancer. J Natl Compr Canc Netw 2013;11(Suppl 5):659-62
   PubMed Web of Science ®Google Scholar
• Protzel C, Seitz AK, Hakenberg OW, et al. [Neoadjuvant, adjuvant and palliative chemotherapy of penile cancer]. Urologe A 2013;52(11):1556-60. 62-3
   PubMedGoogle Scholar
• Zanetta G, Lissoni A, Pellegrino A, et al. Neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel for locally advanced squamous-cell cervical cancer. Ann Oncol 1998;9(9):977-80
   PubMed Web of Science ®Google Scholar
• Sonpavde G, Pagliaro LC, Buonerba C, et al. Penile cancer: current therapy and future directions. Ann Oncol 2013;24(5):1179-89
   PubMed Web of Science ®Google Scholar
• Nicholson S, Hall E, Harland SJ, et al. Phase II trial of docetaxel, cisplatin and 5FU chemotherapy in locally advanced and metastatic penis cancer (CRUK/09/001). Br J Cancer 2013;109(10):2554-9
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Williams DL, Daliani D, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol 2010;28(24):3851-7
   PubMed Web of Science ®Google Scholar
• Spiess PE, Horenblas S, Pagliaro LC, et al. Current concepts in penile cancer. J Natl Compr Cancer Netw 2013;11(5):617-24
   PubMed Web of Science ®Google Scholar
• Pietrantonio F, Biondani P, Verzoni E, et al. Management of advanced genitourinary tumors. Tumori 2012;98(2):264-6
   PubMed Web of Science ®Google Scholar
• Gunia S, Erbersdobler A, Hakenberg OW, et al. C-MET is expressed in the majority of penile squamous cell carcinomas and correlates with polysomy-7 but is not associated with MET oncogene amplification, pertinent histopathologic parameters, or with cancer-specific survival. Pathol Res Pract 2013;209(4):215-20
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144(5):646-74
   PubMed Web of Science ®Google Scholar
• Umbas R, Schalken JA, Aalders TW, et al. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res 1992;52(18):5104-9
   PubMed Web of Science ®Google Scholar
• Campos RS, Lopes A, Guimaraes GC, et al. E-cadherin, MMP-2, and MMP-9 as prognostic markers in penile cancer: analysis of 125 patients. Urology 2006;67(4):797-802
   PubMed Web of Science ®Google Scholar
• Nelson R. Potential prognostic markers in penile cancer. Lancet Oncol 2006;7(5):369
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Meltorn M, Damstrup L, et al. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 2001;12(6):745-60
   PubMed Web of Science ®Google Scholar
• Chaux A, Cohen JS, Schultz L, et al. High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues. Hum Pathol 2012;43(10):1590-5
   PubMed Web of Science ®Google Scholar
• Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006;366(1):2-16
   PubMed Web of Science ®Google Scholar
• Haley JD, Gullick WJ. EGFR signaling networks in cancer therapy. Humana Press, New York, NY; 2008. p. 221-35
   Google Scholar
• Wang D, Su L, Huang D, et al. Downregulation of E-Cadherin enhances proliferation of head and neck cancer through transcriptional regulation of EGFR. Mol Cancer 2011;10:116
   PubMedGoogle Scholar
• Zuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem 2011;112(9):2508-17
   PubMed Web of Science ®Google Scholar
• Baker CH, Kedar D, McCarty MF, et al. Blockade of epidermal growth factor receptor signaling on tumor cells and tumor-associated endothelial cells for therapy of human carcinomas. Am J pathol 2002;161(3):929-38
   PubMed Web of Science ®Google Scholar
• Burtness B, Goldwasser MA, Flood W, et al. Eastern Cooperative Oncology Group. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23(34):8646-54
   PubMed Web of Science ®Google Scholar
• Necchi A, Nicolai N, Colecchia M, et al. Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol 2011;29(22):e650-2
   PubMed Web of Science ®Google Scholar
• Giannatempo P. Early results of the pilot study with the anti-epidermal growth-factor receptor (EGFR) monoclonal antibody panitumumab in patients (PTS) with multi-relapsed or refractory squamous cell Carcinoma (SCC) of the Penis. J Urol 2013;189(No. 4S):e309
   Google Scholar
• Brown A, Ma Y, Danenberg K, et al. Epidermal growth factor receptor-targeted therapy in squamous cell carcinoma of the penis: a report of 3 cases. Urology 2014;83(1):159-65
   PubMed Web of Science ®Google Scholar
• Carthon BC, Ng CS, Pettaway CA, et al. Epidermal growth factor receptor-targeted therapy in locally advanced or metastatic squamous cell carcinoma of the penis. BJU Int 2013
   Web of Science ®Google Scholar
• Plesec TP, Hunt JL. KRAS mutation testing in colorectal cancer. Adv Anat Pathol 2009;16(4):196-203
   PubMed Web of Science ®Google Scholar
• Gou HF, Li X, Qiu M, et al. Epidermal growth factor receptor (EGFR)-RAS signaling pathway in penile squamous cell carcinoma. PLoS One 2013;8(4):e62175
   PubMed Web of Science ®Google Scholar
• Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360(14):1408-17
   PubMed Web of Science ®Google Scholar
• Carlson BC, Hofer MD, Ballek N, et al. Protein markers of malignant potential in penile and vulvar lichen sclerosus. J Urol 2013;190(2):399-406
   PubMed Web of Science ®Google Scholar
• Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56(3):387-437
   PubMed Web of Science ®Google Scholar
• Trelle S, Reichenbach S, Wandel S, et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ 2011;342:c7086
   PubMed Web of Science ®Google Scholar
• Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 2003;169(6):2352-9
   PubMed Web of Science ®Google Scholar
• Shin DM, Zhang H, Saba NF, et al. Chemoprevention of head and neck cancer by simultaneous blocking of epidermal growth factor receptor and cyclooxygenase-2 signaling pathways: preclinical and clinical studies. Clin Cancer Res 2013;19(5):1244-56
   PubMed Web of Science ®Google Scholar
• Golijanin D, Tan JY, Kazior A, et al. Cyclooxygenase-2 and microsomal prostaglandin E synthase-1 are overexpressed in squamous cell carcinoma of the penis. Clin Cancer Res 2004;10(3):1024-31
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Schmittel A, Steiner U, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology 2009;76(5):350-4
   PubMed Web of Science ®Google Scholar
• Mooney D, Paluri R, Mehta A, et al. Update in systemic therapy of urologic malignancies. Postgrad Med 2014;126(1):44-54
   PubMed Web of Science ®Google Scholar
• Zhu Y, Li H, Yao XD, et al. Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int 2010;85(3):334-40
   PubMed Web of Science ®Google Scholar
• Flaherty A, Kim T, Giuliano A, et al. Implications for human papilloma virus in penile cancer. Urol Oncol 2014;32(1):53 e1-8
   PubMed Web of Science ®Google Scholar
• Hellner K, Munger K. Human papillomaviruses as therapeutic targets in human cancer. J Clin Oncol 2011;29(13):1785-94
   PubMed Web of Science ®Google Scholar
• Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009;374(9686):301-14
   PubMed Web of Science ®Google Scholar
• Merck & Co. I. Highlights of prescribing information for gardisil®. product information packet 2011
   Google Scholar
• de Bruijn RE, Heideman DA, Kenter GG, et al. Patients with penile cancer and the risk of (pre)malignant cervical lesions in female partners: a retrospective cohort analysis. BJU int 2013;112(7):905-8
   PubMed Web of Science ®Google Scholar
• Zhai JP, Wang QY, Wei D, et al. [Association between HPV DNA and disease specific survival in patients with penile cancer]. Zhonghua Yi Xue Za Zhi 2013;93(34):2719-22
   PubMedGoogle Scholar
• O’Rorke MA, Ellison MV, Murray LJ, et al. Human papillomavirus related head and neck cancer survival: a systematic review and meta-analysis. Oral Oncol 2012;48(12):1191-201
   PubMed Web of Science ®Google Scholar
• Bezerra AL, Lopes A, Santiago GH, et al. Human papillomavirus as a prognostic factor in carcinoma of the penis: analysis of 82 patients treated with amputation and bilateral lymphadenectomy. Cancer 2001;91(12):2315-21
   PubMed Web of Science ®Google Scholar
• Lont AP, Kroon BK, Horenblas S, et al. Presence of high-risk human papillomavirus DNA in penile carcinoma predicts favorable outcome in survival. Int J Cancer 2006;119(5):1078-81
   PubMed Web of Science ®Google Scholar
• Fonseca AG, Soares FA, Burbano RR, et al. Human papilloma Virus: prevalence, distribution and predictive value to lymphatic metastasis in penile carcinoma. Int Braz J Urol 2013;39(4):542-50
   PubMed Web of Science ®Google Scholar
• Connolly K, Manders P, Earls P, et al. Papillomavirus-associated squamous skin cancers following transplant immunosuppression: one Notch closer to control. Cancer Treat Rev 2014;40(2):205-14
   PubMed Web of Science ®Google Scholar
• Karpanen T, Alitalo K. Lymphatic vessels as targets of tumor therapy? J Exp Med 2001;194(6):F37-42
   PubMed Web of Science ®Google Scholar
• Naumann CM, Al-Najar A, Alkatout I, et al. Lymphatic spread in squamous cell carcinoma of the penis is independent of elevated lymph vessel density. BJU Int 2009;103(12):1655-9. discussion 59
   PubMed Web of Science ®Google Scholar
• Maula SM, Luukkaa M, Grenman R, et al. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res 2003;63(8):1920-6
   PubMed Web of Science ®Google Scholar
• Ferrandiz-Pulido C, Masferrer E, Toll A, et al. mTOR signaling pathway in penile squamous cell carcinoma: pmTOR and peIF4E over expression correlate with aggressive tumor behavior. J Urol 2013;190(6):2288-95
   PubMed Web of Science ®Google Scholar
• Chaux A, Munari E, Cubilla AL, et al. Immunohistochemical expression of the mammalian target of rapamycin pathway in penile squamous cell carcinomas: a tissue microarray study of 112 cases. Histopathology 2014;64(6):863-71
   PubMed Web of Science ®Google Scholar
• Ekshyyan O, Moore-Medlin TN, Raley MC, et al. Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models. BMC Cancer 2013;13:320
   PubMedGoogle Scholar
• Patel V, Marsh CA, Dorsam RT, et al. Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer. Cancer Res 2011;71(22):7103-12
   PubMed Web of Science ®Google Scholar